CALGARY, AB--(Marketwired - Jun 17, 2015) - Hemostemix Inc. (the "Corporation") (TSX VENTURE: HEM), a clinical-stage autologous cell-therapy company, announced today that it has entered into a research collaboration agreement with the Austria-based Ludwig Boltzmann Institute for Experimental and Clinical Traumatology ("LBI") to explore applications of Hemostemix technology for restoring blood supply. LBI is an internationally renowned organization dedicated to research in the fields of tissue engineering, stem cells, and regenerative medicine.
"Collaborating with the Ludwig Boltzmann Institute gives Hemostemix an opportunity to explore in depth the mechanism of action of its lead product ACP-01 for a refined understanding of how ACP-01 fundamentally works to improve blood flow," said Dr. Ina Sarel, vice president of research and development at Hemostemix. "We value LBI's expertise with novel preclinical models that enable us to optimize future applications for ACP-01."
"This research collaboration agreement comes at the right time in the growth of Hemostemix," said Dr. Elmar Burchardt, president and CEO of Hemostemix. "With our multicenter, double-blind, and placebo-controlled phase-2 trial of ACP-01 for critical limb ischemia in progress across international sites under the same clinical protocol, the scientific expertise of the Ludwig Boltzmann Institute will help us develop Hemostemix technology for novel therapeutic applications. Furthermore, demonstrating the mechanism of action of ACP-01 will make Hemostemix more attractive to commercial partners."
About the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology
Based in Vienna, Austria, the Ludwig Boltzmann Institute (LBI) for Experimental and Clinical Traumatology offers state-of-the-art facilities for tissue engineering, including stem-cell research. With its full translational approach and an interdisciplinary team of surgeons, life scientists, and engineers, it provides an optimal research environment in the areas of neuroregeneration, soft-tissue repair, and cartilage and bone regeneration. The LBI facilities feature cell culture laboratories with all associated monitoring capabilities, including flow cytometry, molecular biology, microarray, laser-scanning confocal microscopy, biomaterial characterization, and preclinical in vivo facilities, including full microsurgical setup and extensive imaging capabilities. For more information, visit trauma.lbg.ac.at/en/about-us.
About Hemostemix
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a potential breakthrough stem-cell therapy in an international, multicenter, phase-2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase-2 trial targets a participant's diseased tissue with proprietary cells that are grown from his or her blood and capable of supporting the formation of new blood vessels. Hemostemix currently enrolls participants in the phase-2 trial at four sites in South Africa and two sites in Canada.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM. For more information, visit hemostemix.com or email office@hemostemix.com.
Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
